PDCD1 and lung carcinoma: Recently, the utilization of checkpoint blockade targeting the PD-1/PD-L1 pathway has shown remarkable antitumor responses in patients with advanced melanoma, lung cancer and against other cancers with durable clinical responses23, 24, 25, 26.